Respiratory diseases: what if their progression were tracked in the same way as a brain disease?
AI-generated hypothesis · Pre-publication · To be tested experimentally
Table of contents — full brief
- Hypothesis and mechanismCausal chain, key assumptions, residual unknowns
- State of the artVerified references and counter-evidence (DOIs)
- Falsifiable predictionsQuantitative bounds, statistical tests, H0
- Experimental protocolThree phases — in silico → minimal → full
- Impact analysisNovelty, residual gaps, available data
- Panel reviewFive personas + meta-review
Verified references
5 of 16 references- DOI: 10.1038/s41467-024-50267-3 ↗
Neurostructural subgroup in 4291 individuals with schizophrenia identified using the subtype and stage inference algorithm
2024 - DOI: 10.1093/brain/awad284 ↗
Identification of different MRI atrophy progression trajectories in epilepsy by subtype and stage inference
2023 - DOI: 10.1016/j.ebiom.2023.104835 ↗
Uncovering distinct progression patterns of tau deposition in progressive supranuclear palsy using [18F]Florzolotau PET imaging and subtype/stage inference algorithm
2023 - DOI: 10.1016/j.neuroimage.2023.120005 ↗
Transferability of Alzheimer's disease progression subtypes to an independent population cohort
2023 - DOI: 10.1186/1471-2466-14-164 ↗
Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus
2014
+ 11 more references
Detailed panel scores
The phased structure is well organised, with clear GO/NO-GO/PIVOT criteria that permit objective decision-making and pragmatic adaptation of the protocol in light of interim results.
The hypothesis is judged to be theoretically coherent and is supported by a robust epistemological framework (SuStaIn) already validated in several neurodegenerative and psychiatric pathologies, which justifies its transfer to chronic respiratory diseases. The proposed causal chain is logical and well articulated, with clear stages of collection, modelling, assignment and validation.
The application of SuStaIn to longitudinal data represents a novel approach that has been validated in neurodegenerative diseases, and the selection of well-characterised cohorts such as COPDGene is considered judicious.
A clear and significant addressable market: respiratory medicine (COPD, asthma, pulmonary fibrosis) represents a global market of >$30 billion. The identification of progression subtypes would permit the repositioning of existing drugs (e.g., roflumilast for 'rapid decliners', anti-IL-5 biologics for eosinophilic subtypes) and the enrichment of clinical trials, reducing Phase II/III costs by 30–50%.
A mechanistically strong and falsifiable hypothesis is presented: the application of a validated neuroscience algorithm (SuStAIn) to longitudinal pulmonary function data constitutes an original, high-risk/high-reward approach, with a clear GO/NO-GO protocol that reassures reviewers of the scientific rigour.
Receive the next SPORE hypotheses
Once or twice a month, in your inbox. No spam, one-click unsubscribe.
Your data stays private. No third-party sharing. GDPR-compliant.